© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center
Treating CLL with CALQUENCE® (acalabrutinib)
July 22nd 2021, 6:00pm
More research is needed on how a chronic lymphocytic leukemia diagnosis can affect patients and their caregivers.
July 21st 2021, 6:00pm
TG-1701 monotherapy or added to ublituximab and Ukoniq contributed to early complete responses in patients with B-cell malignancies.
July 18th 2021, 9:00pm
Fixed-duration Venclexta plus Gazyva produced longer remissions than chemoimmunotherapy in elderly patients with chronic lymphocytic leukemia and other comorbidities.
June 16th 2021, 9:00pm
The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.
June 10th 2021, 1:00pm
Treatment with this combination was associated with encouraging clinical responses in this patient population.
June 8th 2021, 4:00pm
Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.
June 7th 2021, 9:00pm
Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.
April 28th 2021, 12:30pm
Don’t let your disease define you
April 23rd 2021, 9:00pm
Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.
April 22nd 2021, 9:00pm
Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.
A Huge Heart for Patients With Lung Cancer
Imperfection After Breast Cancer
Using Group Therapy as a Learning Experience for Patients With Cancer
FDA’s Approval of Keytruda-Based Regimen for Certain Stomach Cancer Subtypes ‘Really Exciting’ For Patients